Prognostic factors related with survival in patients with pancreatic adenocarcinoma

Table 2 Clinical prognostic factors in pancreatic cancer in selected trials

Ref.	No. of patients	Results
Performance status
Sezgin et al[25]	67	PS was an independent prognostic factor for OS
Tas et al[26]	335	Initial poor PS (2-4) was significantly associated with worse survival
DM, obesity and jaundice
Gong et al[31]	510	HR = 1.3 for patients with BMI ≥ 30 compare to those with BMI < 25. But no correlation was found between BMI and survival
Yuan et al[33]	902	Higher baseline BMI was associated with reduced survival
Smith et al[34]	155	The presence of jaundice at the time of surgery was a significant adverse predictor of early survival
Strasberg et al[36]	400	The preoperative jaundice was found to be a significant indicator of poor outcome
Treatment
Park et al[8]	340	mOS, 11.3 vs 10.4 vs 6.4 mo for stage III patients treated with CT, CCRT and BSC, respectively (P < 0.001)
		mOS, 6.4 vs 3.1 mo for patients with stage IV treated with CT or BSC, respectively (P < 0.001)
Lee et al[19]	82	Gemcitabine chemotherapy was found to be the only independent prognostic indicator for OS in advanced pancreatic cancer

DM: Diabetes mellitus; mOS: Median overall survival; PS:Performance status, BMI: Body mass index; CT: Chemotherapy; CCRT: Concurrent chemoradiotherapy; BSC: Best supportive care.